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ABSTRACT Resistance of Lactococcus lactis to cytotoxic
compounds shares features with the multidrug resistance
phenotypeofmammaliantumorcells.Here,wereportthegene
cloning and functional characterization in Escherichia coli of
LmrA, a lactococcal structural and functional homolog ofthe
human multidrug resistance P-glycoprotein MDR1. LmrA is
a 590-aa polypeptide that has a putative topology of six
c-helical transmembrane segments in the N-terminal hydro-
phobic domain, followed by a hydrophilic domain containing
theATP-binding site. LmrAis similartoeach ofthetwo halves
of MDR1 and may function as a homodimer. The sequence
conservation between LmrA and MDR1 includes particular
regions in the transmembrane domains and connecting loops,
which, in MDR1 and the MDR1 homologs in other mamma-
lian species, have been implicated as determinants of drug
recognition and binding. LmrA and MDR1 extrude a similar
spectrum ofamphiphilic cationic compounds, and the activity
of both systems is reversed by reserpine and verapamil. As
LmrAcan be functionallyexpressed inE. coli, itoffers a useful
prokaryotic model for future studies on the molecular mech-
anism of MDR1-like multidrug transporters.
Multidrug resistance poses a serious clinical problem in the
treatment of cancer and infectious diseases and is responsible
for many tens of thousands of deaths each year (1, 2).
Resistance ofhuman cancer cells is commonly associatedwith
high expression levels of the MDR1-encoded P-glycoprotein
(3, 4). Indeed, transfection experiments demonstrate that
overexpression of MDR1 alone can confer multidrug resis-
tance to an otherwise drug-sensitive cell line (5). MDR1 and
related P-glycoproteins are members of the ATP-binding
cassette (ABC) superfamily of transporters (6), whose func-
tions include the ATP-dependent extrusion of amphiphilic
compounds out of the cell (7-9).
Several ABC transporters sharing homology with MDR1
have been identified in microorganisms. Yeast ABC proteins
include the a-mating pheromone transporter STE6 (10) and
the multidrug transporters PDR5 (11) and SNQ2 (12). Fur-
thermore, overexpression of Plasmodium pfMdrl has been
implicated in chloroquine resistance of the malarial parasite
(13, 14). Like MDR1, the characteristic features of these
transporters include the presence of two homologous halves,
each containing an ATP-binding domain, and a membrane
domain composed of several (usually six) putative a-helical
transmembrane segments. The notion that these two halves
must cooperate to the formation of a single transporter is,
amongst others, supported by the observation that the inde-
pendent expression ofeach halfofSTE6 inyeast cells does not
yield a functional transporter, while simultaneous expression
of both halves does (15). Certain ABC proteins, such as the
bacterial a-hemolysin transporter HlyB (16), are half the size
of MDR1 with only a single domain of six transmembrane
segments and a single ABC domain.
In various bacteria, including Lactococcus lactis (17), Bacil-
lus subtilis (18), and Escherichia coli (19), genes encoding
multidrug extrusion systems have beencloned, sequenced, and
functionally expressed. To date, all bacterial multidrug trans-
porters characterized use the proton motive force rather than
ATP as the driving force and act as a drug/H+ antiporter (2).
In previouswork, however,we discovered that one mechanism
ofmultidrug resistance inL. lactis is dependent on drug efflux
by an ATP-dependent transport system (20). This notion
prompted us to search for a putative MDR1-like gene in L.
lactis. Here, we describe the gene cloning and functional
characterization in E. coli of LmrA, a lactococcal ABC-type
multidrug transporter that shares both structural and func-
tional properties with MDR1 and is able to transport multiple
drugs.
MATERIALS AND METHODS
The isolation of the L. lactis MG1363 genomic DNA clone
(6.0-kb Sau 3A DNA fragment in the E. coli cloning plasmid
pUC19) containing the apl and ImrA genes will be described
elsewhere. Nucleotide sequence analysis ofboth DNA strands
was performed using the dideoxynucleotide chain-termination
procedure (21). PCGENE (release 6.8; Genofit, Geneva) was
used for computer-assisted analysis of nucleotide and protein
sequences. Amino acid substitutions said to be conserved are:
A/S/T, D/E, N/Q, R/K, I/L/M/V, and F/Y/W. Protein
secondary structure was predicted from hydropathy profiling
using the algorithm of Kyte and Doolittle (22) with a window
size of 10 residues.
Plasmid pGKLmrA was constructed by subcloning the
2.3-kbSphI-PvuII fragment, containingImrA, into theplasmid
pGK13 harboring a chloramphenicol resistance marker for
positive selection (23). E. coli CS1562 (tolC6::TnlO; ref. 24)
was transformed with plasmid DNA by electroporation (21).
Transformants were selected on Luria broth supplemented
with 25 mM glucose, 16 ,Ag oftetracycline per ml, and 9 ,ug of
chloramphenicol per ml. The sensitivity of transformants to
various drugs was assessed by inoculating exponentially grow-
ing cultures (1:100) into 96-well plates containing serial dilu-
tions of the drugs in the liquid medium described above. The
growth rate at a given drug concentration relative to growth in
its absence was determined as a function of the drug concen-
tration. For Northern blot analysis, total RNA of transfor-
mants was isolated as described (21), 30 ,ug of which was
fractionated on a 2.2 M formaldehyde/1.2% (wt/vol) agarose
gel, transferred to Qiabrane membrane (Qiagen, Westburg,
the Netherlands), and hybridized to the 2.3-kb SphI-PvuII
Abbreviations: ABC, ATP-binding cassette; TPP+, tetraphenylphos-
phonium.
Data deposition: The sequence reported in this paper has been
deposited in the GenBank data base (accession no. U63741).
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DNA fragment. Transcript sizes (in kb) were estimated using
a 0.24- to 9.5-kb RNA ladder (GIBCO/BRL).
To study LmrA-mediated drug transport, cells were har-
vested in the mid-exponential phase, washed, and resuspended
at a protein concentration of0.2 mg/ml in 50 mM potassium-
Hepes (pH 7.5) supplemented with 3 mM MgSO4. Inside-out
membrane vesicles were prepared as described (25) and di-
luted to a protein concentration of 1.0 mg/ml in the Hepes
buffer described above. Ethidium transport in cells and mem-
brane vesicles was measured using fluorescence spectrometry
(20). The uptake of [3H(G)]daunomycin (96.2 GBq/mmol;
New England Nuclear) and N-(4',4'-azo-n-pentyl)-21-deoxy-
[21-3H]ajmalinium (46 GBq/mmol) in membrane vesicles was
assayed via the filtration method (8). The transmembrane
potential (A+p) in cells was measured using a tetraphenylphos-
phonium (TPP+)-selective electrode (26) inthe presence of50
,uM reserpine to inhibit the LmrA-mediated extrusion of
TPP+. In inside-out membrane vesicles, the Aqi was measured
using the fluorescent probe bis-(3-phenyl-5-oxoisoxazol-4-yl)-
pentamethine oxonol (Oxonol V; Molecular Probes). The
transmembrane pH gradient (ApH) in cells and inside-out
membranevesicleswasestimated fromtheincrease in Atf upon
the addition of nigericin at a concentration of 1 nmol per mg
of protein. All experiments were performed at least in tripli-
cate. Standard deviations were calculated where possible, and
these are indicated as ±SD or as error bars in the figures.
RESULTS
The lactococcal MDR1 homolog was discovered in the course
ofwork on theaplgene ofL. lactis MG1363,which encodes an
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alkaline phosphatase-like enzyme. Analysis ofa chromosomal
DNA fragment containing apl revealed a convergently tran-
scribed, 3' adjacent open readingframe of 1770bp, designated
lmrA. The ImrA gene encodes a polypeptide of 590 aa with a
calculated molecular mass of 64,613 Da. Hydropathy analysis
of LmrA suggests the presence of an N-terminal hydrophobic
domain with six putative a-helical transmembrane segments
and a C-terminal hydrophilic domain (data not shown). This
latter domain contains features diagnostic of an ABC-type
ATPase, such as the ABC signature sequence and the Walker
A and B motifs (27).
Comparison of LmrA with members of the ABC protein
superfamilyrevealed the highest overall sequence similarity to
the subfamily of multidrug resistance P-glycoproteins, most
notably human MDR1 and the MDR1 homologin Caenorhab-
ditis elegans. LmrA and each halfofhuman MDR1 share 34%
identical residues with an additional 16% conservative substi-
tutions. The sequence identity between LmrA and the N- and
C-terminal halves of human MDR1 is observed throughout
their lengths (Fig. 1). The membrane domains of LmrA
(residues 1-361) and the N- and C-terminal halves of MDR1
are 23% and 27% identical, respectively, whereas the ABC
domains of the proteins are 48% and 43% identical, respec-
tively. The overall sequence similarity between LmrA and
ABC transporters associated with (i) the uptake ofsolutes, (ii)
antigen presentation, (iii) the excretion of competence or
mating factors, or (iv) the excretion of bacterial antibiotics,
toxins, or polysaccharides is <25% and is mostly confined to
the hydrophilic ABC domains. Interestingly, LmrA shares
overall sequence identity with the E. coli MsbA protein (28%
identical residues), the function of which is unknown at the
I
.MDLEGDRNGGAKKKNFFKLNNKSEKDKK-M9KrVSVFSMFRYSNWLVGTI MGL L- NTD A DS ITNRS
.N F@¶vm M @BEZ-NSEG--KHVKL3UJIS>OK YLF>V- T VAG PQ
ADESKSEIDAILEMSSNDSRSS IRKRSTRRS l-Q ST -PVSIMKLN-LTE Y CAN- A IIFSK
II
IgDElEEDMRYASIgG3 GErIQvF - ^QI} W-I I>FHARQEIS'- HD~NT'-D'sSKINEGDDKIb
MVA--- vnwSAIAAI M RDDKp-HLPTYZ!-- MSS T LMSN
I IVDPER"7.4toNSqN1F FLX TrPWVT.Af Ivln iRPR: _T X
III IV
GM Q Z4ATFFT E8VGFTR G L2Is IS AAVWAKI SSFTDKELLA AFGGQ ELERYNKNLEEAKE
PQ Xl3LI4pGSE>QM Q I6> ZIFPI QKIGWTRQDSF E SKAE
AVIT TI s SFI L IAIAG SGQALKDKE GAG I N TQ KFEYAQSLQV SL
V VI
WCITANISI F3-LIYASYA' jsEY -TVFF - QASPSI A YEIFKIIPPSIDSYSK K
wEg M IF(; MlS T 3 YL -- Ti& EI=STGKLTNLIEEQEV---LH DSS
RXHIIF3ITF FTQA- FSYAGCFR -LVFSAVVFSg P I IMITTZKTPLIDSYST
Walker A
N<N F SQP SXTGQ INVRF IE PVLF
- lKE§SHHfi iDS-e-Q DIt>SI Fl ql FS 3QI ITI @iVSLE Q3FjSAIe
T2BV-TFGEj)Ng VQTRPDIP PGGQT Q- L RPLILFDV
ABC Walker B
IRRN;- VIEKAK-KELKF L
NDLWQjLD s QL I s2 K nc
EIVPrAr Q LLSsV rL
MDR1-N
LmrA
MDR1-C
96
61
734
190
150
aRal
289
249
932
386
343
1029
485
440
1128
583
539
1228
R<VGFzGFD K' KGI rbIM--BDEVNLENA 640
VrZK .FIE GS PL - .... 590
2LIVVFQ Q KGI S ....... 1280
FIG. 1. Comparison of the amino acid sequence of LmrA and the N- and C-terminal halves of the human multidrug resistance P-glycoprotein
MDR1 (3). MDR1-N and MDR1-C represent amino acid residues 1-640 and 641-1280 of MDR1, respectively. The last residue in each row is
numbered. A darkbackground indicates identical residues. The roman numbers refer to the predicted transmembrane a-helices ofLmrA. TheABC
signature sequence and Walker A and B motifs are indicated. Gaps introduced to optimize the alignment are indicated by-.
Biochemistry: van Veen et aL
11- ALPvl&A 0 .3 .510670 Biochemistry: van Veen et al.
present (28), and with the product of an unidentified open
reading frame in B. subtilis (31% identical residues) and
Staphylococcus aureus (33% identical residues) (GenBank
accession nos. P45861 and U29478, respectively). The statis-
tical significance of each alignment score was evaluated using
the DayhoffMDM-78 comparison matrix (29). If an alignment
score is >9 SD above the mean of randomly permuted
sequences (P c 10-19), the sequence similarity is generally
considered to be too large to have arisen either by chance or
by a convergent evolutionary process (30). The significance of
the scoresforthe alignments oftheABCdomainofLmrAwith
the ABC domains of other ABC proteins is >9 SD. For
alignments of the membrane domain of LmrAwith the mem-
brane domains offunctionallyverified ABC-type transporters,
a significance of >9 SD is only observed for the subfamily of
P-glycoproteins, most notably human MDR1 and the MDR1
homolog in C. elegans, but not for specific drug extrusion
systems such as HlyB, STE6, and the doxo- and daunorubicin
transporter DrrAB from Streptomyces peuceticus (ref. 31;
Table 1).
Having established the structural similarity between LmrA
and MDR1,webegan to explore thefunction ofLmrA. Forthis
purpose, lmrA was subcloned into the E. coli/L. lactis shuttle
vector pGK13 (23), giving pGKLmrA. Control and lmrA
containing plasmids were transferred to E. coli strain CS1562,
which is hypersensitive to drugs due to a deficiency in the TolC
protein (24). Northern blot analysis was performed to confirm
the expressionofImrA in this host. Using anlmrA gene-specific
DNAprobe, the 1.8-kb lmrA messenger was readily detectable
in cells harboring pGKLmrA. The signal was absent in the
parental vector control (data not shown).
Two approaches were used to assess the ability of heterolo-
gously expressed LmrA to act as a multidrug extrusion system:
(i) in vivo resistance to growth inhibition by lipophilic cations,
and (ii) transport oflipophilic cations. E. coli CS1562/pGK13
is unable to grow on solid media containing ethidium at
concentrations >20 ,uM. Strikingly, cells harboring pGKLmrA
are able to form colonies onplates containing 60 ,tM ethidium
after overnight incubation at 37°C. This difference in in vivo
drug resistance was studied more extensively in liquid cultures
in the presence of various drugs that are known substrates of
MDR1 (4). The results, depicted in Table 2, show that the
expression of LmrA in E. coli CS1562 increases resistance to
ethidium, daunomycin, rhodamine 6G, and TPP+.
To elucidate the mechanism of LmrA-associated drug re-
sistance, fluorimetric ethidium transport assays were per-
formed. Washed cell suspensions ofE. coli CS1562 containing
pGKLmrA orpGK13 accumulated ethidium at the same initial
rate (Fig. 2). In the control cells, this A4i-driven passive influx
Table 1. Statistical significance of alignments of the membrane
domain of LmrA with the membrane domains of ABC-type
(multi)drug transporters
Transporter Statistical significance
MDR1-N 11.6
MDR1-C 10.8
CE MDR1-C 9.8
CE MDR1-N 9.0
HlyB 7.3
STE6-C 7.3
STE6-N 5.3
DrrB -0.5
The GenBank database accession nos. are indicated in parentheses:
human MDR1 (P08183), CE MDR1 in C. elegans (P34712), HlyB in
E. coli (M81823), STE6 in Saccharomyces cerevisiae (P12866), and
DrrB in Streptomyces peucetidus (M73758). The N- and C-terminal
halves ofMDR1, CE MDR1, and STE6 are indicated bythe extensions
N and C, respectively. The sequence comparisons were repeated with
150 permutations using a gap penalty of 80.
Table 2. Effect oflmrA gene expression on the relative resistance
to drugs of E. coli CS1562
Drug Relative resistance
Ethidium 41 ± 6
Daunomycin 32 ± 5
Rhodamine 6G 45 ± 8
TPP+ 54 ± 5
Relative resistances were determined by dividing the IC50 (the drug
concentration required to inhibit the growth rate by 50%) for cells
harboring pGKLmrA by the IC50 for control cells harboring pGK13.
The latter values varied between 4 and 5 ,uM for the drugs tested.
of the lipophilic cation was enhanced upon energization with
glucose, due to the increase of the A1i (interior negative) and
ApH (interior alkaline) from -67 to -90 mV and from -5 to
-9 mV, respectively (data not shown). Although comparable
changes in Aip and ApH were observed in LmrA-expressing
cells, energization with glucose resulted in the extrusion of
ethidium rather than uptake (Fig. 2). Hence, drug resistance
in LmrA-expressing cells is based on active drug efflux.
Theenergetics andspecificityofLmrA-mediateddrugtrans-
port were studied in more detail in inside-out membrane
vesicles. Daunomycin uptake above equilibration levels was
observed inmembranevesicles ofLmrA-expressingcells in the
presence ofATP, an ATP-regenerating system, and the iono-
phores valinomycin plus nigericin that selectively dissipate the
A/p (interior positive) and ApH (interior acidic), respectively
(Fig. 3A). The dissipation of the components of the proton
motive force by the ionophores was confirmed in experiments
in which the fluorescent probe Oxonol V was used to monitor
the Atr. Daunomycin was not accumulated in these membrane
vesicles in the presence of ATPyS, a non-hydrolyzable ATP
analog, indicating that ATP hydrolysis is required for trans-
port. This conclusion was confirmed by the inhibition ofactive
daunomycin uptake by ortho-vanadate, an inhibitor of ABC
GK13
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FIG. 2. Ethidium transport inE. coli CS1562with (pGKLmrA) and
without (pGK13) expression ofLmrA. Ethidium was added towashed
cell suspensions at a final concentration of 50 ,uM. Cells were
energized by the addition of 10 mM glucose (G).
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FIG. 3. Daunomycin transport in inside-out membrane vesicles.
(A) Uptake ofdaunomycin (3.8 ,uM, finalconcentration) in membrane
vesicles prepared from E. coli CS1562/pGKLmrA (-, M) and E. coli
CS1562/pGK13 (a, O), in the presence ofvalinomycin plus nigericin
(each at 1 nmol per mg of protein), 5 mM creatine phosphate, and 1
mM ATP-yS (0, 0) or 1 mM ATP plus 0.1 mg of creatine kinase per
ml (-, O). (B) Effect ofinhibitors on daunomycin uptake in inside-out
membrane vesicles ofLmrA-expressing cells. Inhibitors were included
in the assay at a final concentration of 50 ,uM. The initial rate of
ATP-dependent daunomycin uptake in membrane vesicles over the
transporters andP-typeATPases (Fig. 3B). Membranevesicles
prepared from control cells did not display the ATP-
dependent uptake of daunomycin (Fig. 3A). Similar results
were obtained for the transport of N-(4',4'-azo-n-pentyl)-21-
deoxy-ajmalinium, a high-affinity substrate ofMDR1 (32) and
ethidium (data not shown). The inhibition of daunomycin
uptake in inside-out membrane vesicles of LmrA-expressing
cells by a 12-fold excess of ethidium, rhodamine 6G, or TPP+
points tocompetitionbetweenthese substrates fortransportby
LmrA (Fig. 3B). Finally, LmrA-mediated drug transport was
inhibited by a 12-fold excess of reserpine (Fig. 3B) and
verapamil (data not shown). Both compounds are well-known
inhibitors of human MDR1 (4).
DISCUSSION
In prokaryotes, a number of dedicated ABC-type drug export
systems have been detected. A well-known example is Strep-
tomyces, in which transporters such as DrrAB mediate the
excretion ofspecific antibiotics to ensure self-resistance to the
antibiotics the organism produces. To our knowledge, the
lactococcal LmrAprotein describedinthiswork represents the
first prokaryotic ABC transporter able to transport multiple
drugs withdifferent chemical structures andcellulartargets. In
view of the general organization of ABC transporters, two
membrane domains and two ATP-binding domains (6), LmrA
is postulated to function as a homodimer unit (or a multimeric
complex derived thereof).
LmrA is a true prokaryotic homolog of MDR1. The struc-
tural similarity between the ABC and membrane domains of
LmrA and the N- and C-terminal halves of MDR1 (Fig. 1)
translates into a functional similarity. Both proteins mediate
the extrusion of amphiphilic cationic compounds, and the
activity of both transporters is reversed by reserpine, vera-
pamil, and vanadate (Figs. 2 and 3). The observation of
ATP-dependent, LmrA-mediated daunomycin transport in
inside-outmembranevesicles intheabsence ofaprotonmotive
force points to a direct drug transport mechanism inwhich the
transport protein physically interactswith the drug. It hasbeen
suggested that MDR1 removes drugs from the membrane
rather than from the cytoplasm (33). Recently, evidence has
been obtained that LmrA expels drugs from the inner leaflet
of the lipid bilayer (34). Thus, the ability of amphiphilic
substrates to partition in the inner leaflet of the membrane is
aprerequisite for the recognitionby the multidrug transporter
and is the first step in specificity. The subsequent interaction
between drugs and a fairly nonspecific binding site on the
transport protein will be the second determinant of drug
specificity. Interestingly, the sequence conservation in the
membrane domain of LmrA includes particular regions (e.g.,
the first cytoplasmic loop and the region comprising trans-
membrane segments V and VI) that have been implicated as
determinants of drug recognition and binding by human
MDR1 and by MDR1 homologs in other mammalian species
(35).
Appreciation of the mechanisms by which eukaryotic and
prokaryotic cells develop drug resistance is critical for the
development ofeffective new drugs. Studies on the molecular
mechanism of-LmrA may offer a useful framework for inter-
preting data obtained on its medically important counterparts
in humans and pathogenic microorganisms.
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